PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Size ($80.1 Billion Revenue By 2028) Growing Rapidly with Recent Trends and Outlook

"The new report published by The Business Research Company, titled PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $39.8 billion in 2023 to $46.29 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $80.1 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=10788&type=smp

Rising Cancer Prevalence Drives Surge In Pd-1 And Pd-L1 Inhibitors Market
The rising prevalence of cancer cases is expected to propel the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market going forward. Cancer is a condition when some cells develop uncontrollably and spread to other body parts. PD-1 and PD-L1 inhibitors help to treat cancer by harnessing the body's immune system to fight cancer cells. Hence, the rising cancer cases contribute to the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market. For instance, in October 2023, according to the European Union Science Hub, a Belgium-based joint research centre of the European Commission, in the two years before to 2022, the number of new cancer cases rose by 2.3%, reaching 2.74 million. Likewise, during the previous two years, there was a 2.4% rise in cancer-related deaths. Therefore, the rise in the prevalence of cancer cases will fuel the growth of the PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market.

Innovative Strides Bristol-Myers Squibb's Opdualag Marks A Milestone In Pd-1 And Pd-L1 Inhibitors Market With Fda Approval
Product innovation has emerged as a key trend gaining popularity in the PD-1 and PDL1 Inhibitors/ immune checkpoint inhibitors market. Major market players are concentrating their efforts on creating innovative products to strengthen their position in the market. For instance, In March 2022, Bristol-Myers Squibb, a US-based pharmaceutical company, received FDA approval for Opdualag, which is a fixed-dose combination of nivolumab (Opdivo) and relatlimab, which is a LAG-3 inhibitor. Opdualag is the first LAG-3 inhibitor to receive approval from the US Food and Drug Administration (FDA) to treat patients with metastatic melanoma. The combination of nivolumab and relatlimab in Opdualag aims to enhance the immune response against cancer cells.

The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market covered in this report is segmented -
1) By Product: Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab
2) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
3) By Application: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications
4) By End-Users : Hospitals, Specialty Clinics, Academic and Research Institutions

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=10788&type=discount

Major companies operating in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Dr. Reddy's Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd, Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.

Contents of the report:
1. Executive Summary
2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Report Structure
3. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Trends And Strategies
4. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market - Macro Economic Scenario
5. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Size And Growth
…..
27. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/pd-1-and-pdl1-inhibitors-or-immune-checkpoint-inhibitors-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.